Currently there are three platinum anticancer drugs on the market: cisplatin, oxaliplatin, and carboplatin. These compounds have variable leaving ligands, which are the locations on compounds that will be replaced by biological targets (DNA and protein). The purpose of this research is testing platinum compounds that have a nonleaving ethylenediamine or diaminocyclohexane ligand, similar to the nonleaving ligands found in cisplatin and oxaliplatin, and variable leaving ligands. Three compounds were tested including oxaliplatin, ethylenediamine(oxalato)platinum(II) (Pt(en)(ox)), and dichloro(ethylenediamine)platinum(II) (Pt(en)Cl2). MTT assays were performed on cancer cells treated with the platinum compounds for twenty-four hours. In MTT assays, the living cells can reduce a tetrazolium salt to a purple formazan that is quantified to determine percent cell survival. The testicular cancer cell line NTERA-2 showed a higher sensitivity to Pt(en)(ox) than the colorectal cancer cell line HT-29. The NTERA-2 cells were 2.5 times more sensitive to Pt(en)(ox) than to the therapeutic standard oxaliplatin. Also, the HT-29 and NTERA-2 cancer cell lines had similar toxicities to oxaliplatin.
Advisor(s) or Committee Chair
Duke, Brooke, "Toxicity of Platinum Containing Compounds with Variable Leaving Ligands on Cancer Cells" (2016). Honors College Capstone Experience/Thesis Projects. Paper 621.